IDEA Collider: Innovation & Asymmetric Learning in Pharma

Building the Future of Targeted Protein Degradation Medicines with Nello Mainolfi

Episode Notes

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation. 

 

Episode Timestamps; 

00:00 Welcome to Idea Collider 

00:18 Kymera 2026 Catalysts 

02:33 De Risking with Degraders 

02:54 Targeted Protein Degradation 101 

06:20 KT-621 STAT6 Degrader

08:16 Rethinking Type 2 Disease Treatment

12:21 Nello’s Path to CEO 

16:32 Building a Standalone Biotech 

23:19 Partnering with Big Pharma 

26:51 Culture and Office Energy 

32:03 Capital Plan and Potential Launches

36:24 Belief and Execution Mindset 

39:00 Life Outside the Lab 

40:07 Where to Follow Kymera 

40:35 Closing Thanks 

 

Don't forget to Like, Share, Subscribe, Rate, and Review!   

 

Keep up with Nello Mainolfi & Kymera

LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/

Website: https://www.kymeratx.com/   

 

Follow IDEA Pharma On; 

Website: https://www.ideapharma.com/ 

LinkedIn: https://www.linkedin.com/company/idea-pharma/   

 

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/